Issued 2026-08-13 at $15.05 · now $15.14 (2026-08-13, +0.6% since)
Based on its own history, a month from the 2026-08-13 close, CRVS has typically landed between $10.54 and $23.28 — a range of −30.0% to +54.7% from the issuance price $15.05.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,589 overlapping 1 month windows · 2016-03-23 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($15.05) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where CRVS has typically landed a month from the 2026-08-13 close of $15.05 — the range is history, not a prediction.
- now $15.14 (+0.6%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $15.18 (+0.9%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $12.39–$17.97
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $10.54–$23.28
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-13 | −60.5% | −60.5% | +3.4% |
| 2020-02-18 | −59.7% | −60.2% | +4.1% |
| 2020-02-14 | −56.1% | −59.8% | +5.1% |
| 3 best | |||
| 2021-08-19 | +351.3% | +0.0% | +351.3% |
| 2021-08-20 | +292.1% | +0.0% | +346.6% |
| 2021-08-25 | +245.5% | −2.7% | +284.2% |
2,589 overlapping windows · 2016-03-23 – 2026-08-13 · not cherry-picked
Pending catalysts
- June 2027 — Trial primary completion: Phase 2 primary completion: Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD (source, as of 2026-08-14)
- November 2027 — Trial primary completion: Phase 3 primary completion: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~11 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.